The oral efficacy of ZB716 was further verified in the second in vivo experiment using a PDX mouse model hosting an ER+/PR+/Her2- primary breast tumor (Figure 7) where both ZB716 dose groups showed regression of tumor comparable to the fulvestrant group. This evidence concerns the gene ESR1 and breast neoplasm.